Jakob Grunnet Knudsen

Jakob Grunnet Knudsen

Auto-generated profile, based on publicly available information

Jakob Grunnet Knudsen

Section for Cell Biology and Physiology, Department of Biology, University of Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JKJakob G. Knudsen
Jakob G. Knudsen
MMMaria Murholm
Maria Murholm
ACAndrew Carey
Andrew Carey
RBRasmus S. Biensø
Rasmus S. Biensø
ABAstrid L. Basse
Astrid L. Basse
HPHenriette Pilegaard
Henriette Pilegaard
Expression of brown adipose tissue (BAT) associated proteins like uncoupling protein 1 (UCP1) in inguinal WAT (iWAT) has been suggested to alter iWAT metabolism. The aim of this study was to investigate the role of interleukin-6 (IL-6) in exercise training and cold exposure-induced iWAT UCP1 expression. The effect of daily intraperitoneal injections of IL-6 (3 ng/g) in C57BL/6 mice for 7 days on iWAT UCP1 expression was examined. In addition, the expression of UCP1 in iWAT was determined in response to 3 days of cold exposure (4°C) and 5 weeks of exercise training in wild type (WT) and whole body IL-6 knockout (KO) mice. Repeated injections of IL-6 in C57BL/6 mice increased UCP1 mRNA but not UCP1 protein content in iWAT. Cold exposure increased iWAT UCP1 mRNA content similarly in IL-6 KO and WT mice, while exercise training increased iWAT UCP1 mRNA in WT mice but not in IL-6 KO mice. Additionally, a cold exposure-induced increase in iWAT UCP1 protein content was blunted in IL-6 KO mice, while UCP1 protein content in iWAT was lower in both untrained and exercise trained IL-6 KO mice than in WT mice. In conclusion, repeated daily increases in plasma IL-6 can increase iWAT UCP1 mRNA content and IL-6 is required for an exercise training-induced increase in iWAT UCP1 mRNA content. In addition IL-6 is required for a full induction of UCP1 protein expression in response to cold exposure and influences the UCP1 protein content iWAT of both untrained and exercise trained animals.

11 January 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
EVElisa Vergari
Elisa Vergari
JKJakob G. Knudsen
Jakob G. Knudsen
RRReshma Ramracheya
Reshma Ramracheya
SSS Albert Salehi
S Albert Salehi
QZQuan Zhang
Quan Zhang
PRPatrik Rorsman
Patrik Rorsman
Hypoglycaemia (low plasma glucose) is a serious and potentially fatal complication of insulin-treated diabetes. In healthy individuals, hypoglycaemia triggers glucagon secretion, which restores normal plasma glucose levels by stimulation of hepatic glucose production. This counterregulatory mechanism is impaired in diabetes. Here we show in mice that therapeutic concentrations of insulin inhibit glucagon secretion by an indirect (paracrine) mechanism mediated by stimulation of intra-islet somatostatin release. Insulin’s capacity to inhibit glucagon secretion is lost following genetic ablation of insulin receptors in the somatostatin-secreting δ-cells, when insulin-induced somatostatin secretion is suppressed by dapagliflozin (an inhibitor of sodium-glucose co-tranporter-2; SGLT2) or when the action of secreted somatostatin is prevented by somatostatin receptor (SSTR) antagonists. Administration of these compounds in vivo antagonises insulin’s hypoglycaemic effect. We extend these data to isolated human islets. We propose that SSTR or SGLT2 antagonists should be considered as adjuncts to insulin in diabetes therapy.

1 June 2018 in Cell Reports
Verified
Journal Article
Open access
LBLinford J.B. Briant
Linford J.B. Briant
MDMichael S. Dodd
Michael S. Dodd
MCMargarita V. Chibalina
Margarita V. Chibalina
NRNils J.G. Rorsman
Nils J.G. Rorsman
PJPaul R.V. Johnson
Paul R.V. Johnson
JKJakob G. Knudsen
Jakob G. Knudsen
Glucagon, the principal hyperglycemic hormone, is secreted from pancreatic islet α cells as part of the counter-regulatory response to hypoglycemia. Hence, secretory output from α cells is under high demand in conditions of low glucose supply. Many tissues oxidize fat as an alternate energy substrate. Here, we show that glucagon secretion in low glucose conditions is maintained by fatty acid metabolism in both mouse and human islets, and that inhibiting this metabolic pathway profoundly decreases glucagon output by depolarizing α cell membrane potential and decreasing action potential amplitude. We demonstrate, by using experimental and computational approaches, that this is not mediated by the KATP channel, but instead due to reduced operation of the Na+-K+ pump. These data suggest that counter-regulatory secretion of glucagon is driven by fatty acid metabolism, and that the Na+-K+ pump is an important ATP-dependent regulator of α cell function.

21 March 2018 in Diabetes
Verified
Journal Article
Open access
PDF file
AHAlexander Hamilton
Alexander Hamilton
QZQuan Zhang
Quan Zhang
SSS Albert Salehi
S Albert Salehi
MWMara Willems
Mara Willems
JKJakob G. Knudsen
Jakob G. Knudsen
ATAndrei Tarasov
Andrei Tarasov
Adrenaline is a powerful stimulus of glucagon secretion. It acts by activation of β-adrenergic receptors, but the downstream mechanisms have only been partially elucidated. Here, we have examined the effects of adrenaline in mouse and human α-cells by a combination of electrophysiology, imaging of Ca2+ and PKA activity, and hormone release measurements. We found that stimulation of glucagon secretion correlated with a PKA- and EPAC2-dependent (inhibited by PKI and ESI-05, respectively) elevation of [Ca2+]i in α-cells, which occurred without stimulation of electrical activity and persisted in the absence of extracellular Ca2+ but was sensitive to ryanodine, bafilomycin, and thapsigargin. Adrenaline also increased [Ca2+]i in α-cells in human islets. Genetic or pharmacological inhibition of the Tpc2 channel (that mediates Ca2+ release from acidic intracellular stores) abolished the stimulatory effect of adrenaline on glucagon secretion and reduced the elevation of [Ca2+]i. Furthermore, in Tpc2-deficient islets, ryanodine exerted no additive inhibitory effect. These data suggest that β-adrenergic stimulation of glucagon secretion is controlled by a hierarchy of [Ca2+]i signaling in the α-cell that is initiated by cAMP-induced Tpc2-dependent Ca2+ release from the acidic stores and further amplified by Ca2+-induced Ca2+ release from the sarco/endoplasmic reticulum.

1 September 2010 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
LLLotte Leick
Lotte Leick
JFJoachim Fentz
Joachim Fentz
RBRasmus S. Biensø
Rasmus S. Biensø
JKJakob G. Knudsen
Jakob G. Knudsen
JJJacob Jeppesen
Jacob Jeppesen
HPHenriette Pilegaard
Henriette Pilegaard
We tested the hypothesis that repeated activation of AMP-activated protein kinase (AMPK) induces mitochondrial and glucose membrane transporter mRNA/protein expression via a peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α)-dependent mechanism. Whole body PGC-1α-knockout (KO) and littermate wild-type (WT) mice were given either single or repeated subcutaneous injections of the AMPK activator AICAR or saline. Skeletal muscles were removed either 1 or 4 h after the single AICAR treatment or 24 h after the last injection following repeated AICAR treatment. Repeated AICAR treatment increased GLUT4, cytochrome (cyt) c oxidase I, and (cyt) c protein expression ∼10–40% relative to saline in white muscles of WT but not of PGC-1α-KO mice, whereas fatty acid translocase/CD36 (FAT/CD36) protein expression was unaffected by AICAR treatment in both genotypes. GLUT4, cyt c, and FAT/CD36 mRNA content increased 30–60% 4 h after a single AICAR injection relative to saline in WT, and FAT/CD36 mRNA content decreased in PGC-1α-KO mice. One hour after a single AICAR treatment, phosphorylation of AMPK and the downstream target acetyl-coenzyme A carboxylase increased in all muscles investigated independent of genotype, indicating normal AICAR-induced AMPK signaling in the absence of PGC-1α. The hexokinase II (HKII) mRNA and protein response was similar in muscles of WT and PGC-1α-KO mice after single and repeated AICAR treatments, respectively, confirming that HKII is regulated independently of PGC-1α in response to AICAR. In conclusion, here we provide genetic evidence for a role of PGC-1α in AMPK-mediated regulation of mitochondrial and glucose membrane transport protein expression in skeletal muscle.

1 February 2019 in Cell Metabolism
Verified
Journal Article
Open access
JKJakob G. Knudsen
Jakob G. Knudsen
AHAlexander Hamilton
Alexander Hamilton
RRReshma Ramracheya
Reshma Ramracheya
ATAndrei Tarasov
Andrei Tarasov
MBMelissa Brereton
Melissa Brereton
PRPatrik Rorsman
Patrik Rorsman
Diabetes is a bihormonal disorder resulting from combined insulin and glucagon secretion defects. Mice lacking fumarase (Fh1) in their β cells (Fh1βKO mice) develop progressive hyperglycemia and dysregulated glucagon secretion similar to that seen in diabetic patients (too much at high glucose and too little at low glucose). The glucagon secretion defects are corrected by low concentrations of tolbutamide and prevented by the sodium-glucose transport (SGLT) inhibitor phlorizin. These data link hyperglycemia, intracellular Na+ accumulation, and acidification to impaired mitochondrial metabolism, reduced ATP production, and dysregulated glucagon secretion. Protein succination, reflecting reduced activity of fumarase, is observed in α cells from hyperglycemic Fh1βKO and β-V59M gain-of-function KATP channel mice, diabetic Goto-Kakizaki rats, and patients with type 2 diabetes. Succination is also observed in renal tubular cells and cardiomyocytes from hyperglycemic Fh1βKO mice, suggesting that the model can be extended to other SGLT-expressing cells and may explain part of the spectrum of diabetic complications.